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S256 Poster Session IITo address this, non-irradiated female BALB/C mice were trans-
planted with 5-6107 whole bone marrow (WBM) cells from male
BALB/C mice daily for four day on week zero, then again on week
eight (4.5108 cells total/mouse), or an equal volume of diluent
(control). On week 24, transplanted mice received 1000 cGy of
chest-only radiation or no radiation. On week 32, histochemical
and immunohistochemical analyses were performed on recipient’s
lungs.
Bone marrow chimerism was not significantly different in the irra-
diated and non-irradiated cohorts at the time of sacrifice (average
45.11 + 6.25% Y chromosome+, all mice). Recipient lungs contained
few non-hematopoietic donor marrow-derived cells. These cells
were exclusively epithelial (Y+/cytokeratin+), primarily type II pneu-
mocytes (Y+/prosurfactant C+), while no endothelial (Y+/von Wille-
brand+) or vascular smooth muscle (Y+/alpha-actin+) cells were
identified. Irradiated and non-irradiated cohorts had similar quanti-
ties of these cells (0.80 + 0.22% vs. 0.51 + 0.08% Y+/cytokeratin+;
0.37 + 0.08% vs. 0.32 + 0.12% Y+/prosurfactant C+, p. 0.2). Pul-
monary vessel wall thickness-to-blood vessel diameter ratios
(PVWT/D) were significantly increased in the non-irradiated cohort
compared with controls and these ratios were further increased in the
irradiated cohort (141 + 5.75%, 161 + 5.34% of control, p\0.05
comparing all groups).
These data indicated that marrow cell infusion alone results in pul-
monary vascular remodeling, and this effect is augmented by radia-
tion injury. These changes are independent of transplanted
marrow cell conversion to pulmonary vascular endothelial, smooth
muscle cells. These studies suggest that transplanted cells may be
lung toxic entities in the setting of clinical BMT.266
MODELS OF STEM CELL TRANSPLANTATION FOR THE REPAIR OF NON-
HEMATOPOIETIC TISSUES
Annett, G., Wirthlin, L., Pepper, K., Sondergaard, C., McGee, J.,
Lindsey, M., Zhou, P., Bauer, G., Nolta, J. University of California,
Davis, Sacramento, CA
Human stem cells from adult sources have been shown, in our lab-
oratory and others, to promote the repair of damaged tissues. Differ-
ent populations of stem cells contribute to the regeneration of
muscle, neural tissue, liver, heart, and vasculature, although the
mechanisms by which they accomplish this are still not well under-
stood. We and others have shown that stem cells home to hypoxic
and/or inflamed areas, and release bioactive factors that can suppress
the local immune system, enhance angiogenesis, inhibit fibrosis and
apoptosis, and stimulate recruitment, retention, mitosis and differ-
entiation of endogenous tissue-residing stem cells. These trophic ef-
fects are distinct from the direct differentiation of stem cells into the
tissue to be regenerated. To actually rebuild a non-hematopoietic
tissue, the differentiated progeny of embryonic or induced pluripo-
tent stem cells will be required. We have focused on improving ro-
dent models in which to examine human stem cell-mediated
disease correction and tissue repair, focusing primarily on liver re-
generation and hypoxic tissue models of peripheral vascular disease
and cardiac ischemia. Most recently we are studying mesenchymal
stem cell–mediated repair of neural damage. We are interested in
the mechanisms by which stem cells of different types and origins
home preferentially into areas of tissue damage, and we seek to im-
prove the robustness. To track cells into the damaged tissues in
vivo, we have labeled them with fluorophore – conjugated iron oxide
nanoparticles and have used novel mouse models that facilitate hu-
man cell detection. We have also used 19F magnetic resonance im-
aging for stem cell tracking with multiple unique perfluorocarbon
nanobeacons, human/murine centromeric FISH, immunohisto-
chemistry and quantitative PCR. Using these technologies, we
have shown that human stem cells migrate from the bloodstream
randomly and in moderate numbers throughout all tissues examined
in cases of chronic disease or following sublethal irradiation, but that
in instances of acute damage, the homing is more vigorous and spe-
cific to the site of damage. Pre-culture in hypoxia dramatically alters
the phenotype and migratory characteristics of human mesenchymal
stem cells. We are applying this knowledge to tissue repair strategies,
to allow enhanced numbers of stem cells to migrate to the areas of
hypoxic damage, to exert trophic effects that initiate revasculariza-
tion and cascades of repair.SUPPORTIVE CARE
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CIDOFOVIR TREATMENT OF BK-VIRUS RELATED HEMORRHAGIC CYSTI-
TIS EARLY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT)
FOR MALIGNANT DISEASES
Chu, D.T.1, Gulbis, A.M.2, Howell, J.E.2, de Lima, M.1, Matteo, P.1,
Ciurea, S.1, Thall, P.F.1, Champlin, R.E.1, Andersson, B.S.1 1 University
of Texas M.D. Anderson Cancer Center, Houston, TX; 2 University of
Texas M.D. Anderson Cancer Center, Houston, TX
Background:BK virus infection has been associated with late on-
set hemorrhagic cystitis (HC) after HSCT. Based on data sug-
gesting that cidofovir has activity against BK virus we treated
patients with symptomatic HC and high BK virus titers with ci-
dofovir, we now review the outcome of 32 patients undergoing
this therapy.
Patients andMethods: The patients studied had undergone alloge-
neic HSCT for leukemia (28), MDS (1), lymphoma (2), and ovarian
cancer (1), and presented with UTI symptoms including (any combi-
nation of) hematuria, urgency, and pain, and a high-titer of BK-virus.
Patients received treatment with either once weekly (1-5 mg/kg), or
divided 3  weekly/every other day (0.25-0.5 mg/kg/dose). All pa-
tients received forced hydration. On the once-weekly schedule 22/
23 patients received probenecid and 1/9 in the higher frequency
schedule received probenecid. Semi-quantitative BK virus assay
was performed prior to and following cidofovir.
Results: A total of 32 patients were treated and the median age was
44 years (range, 23-64), with 17 males and 15 females. Donors were
related (n5 13), unrelated (n5 11), haploidentical (n5 2), and un-
related cord blood (CB) (n5 6). The conditioning regimen was mye-
loablative in 23 pts (72%) and reduced intensity in 9 pts (28%). 24/32
pts (75%) had developed GVHD and were on steroids when diag-
nosed with BK-UTI. Cidofovir was well tolerated with no subjects
developing renal insufficiency. The majority of symptoms were re-
solved within 10 days from cidofovir initiation but the limited num-
ber of subjects precluded a formal comparison between dosing
subgroups (Table 1).
The viral load did not change significantly when assessed at a me-
dian of 24 days after start of cidofovir (median of$3.9 107 copies/
mL). However, patients who were re-assayed at later time points
(median 68 days) had a viral load less than 1% of the initial value (me-
dian 4.9105 copies/mL).
We conclude that cidofovir appears promising as treatment for
BK-virus related hemorrhagic cystitis. The frequent administra-
tion-schedule is relatively easy to administer without the need for
probenecid. More data are needed to determine an optimal cidofovir
dosing schedule, and optimal time to reassess BK virus load by PCR
in allogeneic HSCT patients.
Table 1. Hemorrhagic cystitis symptom response
Hematuria Urgency Cramp/Spasm Pain CBIPre Cidofovir 28 (88%) 27 (85%) 25 (78%) 30 (94%) 13 (41%)
Post Cidofovir 6 (18%) 9 (28%) 1 (3%) 9 (28%) 1 (3%)CBI5 continuous bladder irrigation.268
A PHASE 1 DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY AND
PHARMACOKINETICS OF PALIFERMIN IN PEDIATRIC SUBJECTS WITH
ACUTE LEUKEMIAS UNDERGOING MYELOABLATIVE THERAPY AND AL-
LOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT
Morris, J.1, Neudorf, S.2, Moore, T.3, Shah, A.4, Graham, M.5,
Aquino, V.6, Duerst, R.7, Neidler, M.8, deChateau, M.9, Berger, D.10,
Morris, C.1 1 Loma Linda University Medical Center, Loma Linda, CA;
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Poster Session II S257Background: Palifermin at 60ug/kg/dose, decreases the severity of
oral mucositis (OM) in adults with hematologic malignancies
undergoing SCT. Currently there is no proven therapy to decrease
severe OM in pediatric subjects receiving chemotherapy +/- radia-
tion for SCT. Reducing severe OM in pediatrics should decrease
infection, pain, and enteral nutrition use and improve outcome
following SCT.
Study Design: Phase 1 dose escalation study of palifermin to deter-
mine the safety and dosing for pediatric subjects with acute leuke-
mia’s undergoing myeloablative allogeneic SCT.
Conditioning regimen: Palifermin SCT Days -10 to -8 and 0 to
+2, 1200 cGy (200 cGy  6 fractions) TBI, etoposide 1500 mg/m2,
and cyclophosphamide 120 mg/kg.
24 patients have been enrolled. Three age groups studied: 1 to 2, 3
to 11, and 12 to 16 years old. Three dose levels studied: 40, 60, and
80ug/kg/day. All groups have completed enrollment except 1 to 2
year group at 80ug/kg/dose.
Results: Safety data-no deaths, dose limiting toxicities (DLT), or
treatment related serious adverse events (SAE’s). The most common
adverse event related to palifermin was rash, 6/24 subjects (4/6 in the
80, and 1/9 in the 60 and 40 ug/kg/dose groups), followed by puritis,
3/24 subjects (2/6 in the 80 and 1/9 in the 60 ug/kg/dose group).
Pharmacokinetic data was not sufficient to show if linear pharma-
cokinetics occurs or if age impacts the pharmacokinetics in pediat-
rics. No accumulation of palifermin after 3 consecutive daily doses
occurred. Antibodies to palifermin were not seen on blood samples
obtained on SCT day -10, +30 and +100. OM grades 3 and 4 were
seen in 3/9 subjects receiving 40, 5/9 receiving 60, and 0/6 receiving
80 ug/kg/dose. 6/24 subjects had . grade 2 graft versus host
disease.
Conclusion: 1. No DLT’s and no SAE’S in any of the completed
age/dose groups. The 1 to 2 year group continues to enroll at 80
ug/kg/dose with no DLT’s or SAE’’s in the 40 and 60 ug/kg/dose
levels.
2. No grade 3/4 OM occurred in the 80 ug/kg/dose, suggesting
a relationship between palifermin dosing and severity of OM.
3. The data review team recommended a palifermin dose of 80 ug/
kg/dose for 3 to 11 and 12 to 16 year old age groups for future effi-
cacy studies. The incidence of OM was less and no SAE’s at this dose,
however the number of patients this is based on is small.
4. Recommendations for future efficacy studies for the 1 to 2 age
group will be made when the 80 ug/kg dose is completed.269
RECOMBINANT BACTERICIDAL PERMEABILITY INCREASING PROTEIN
(RBPI21) FOR ENDOTOXIN (LIPOPOLYSACCHARIDE, LPS) NEUTRALIZA-
TION DURING HEMATOPOIETIC STEM CELL TRANSPLANTATION
(HSCT): PHASE I/II CLINICAL TRIAL RESULTS
Guinan, E.C.1,2, Avigan, D.E.3, Soiffer, R.J.1,7, Bunin, N.J.4,
Russell, J.D.1, Stoler-Barak, L.2, Gallington, L.C.2, Walker, P.6,
Scannon, P.J.5, Levy, O.2 1 Dana Farber Cancer Institute, Boston, MA;
2 Children’s Hospital, Boston, MA; 3 Beth Israel Deaconess Medical Center,
Boston, MA; 4 Children’s Hospital of Philadelphia, PA; 5 Xoma (US) LLC,
Berkeley, CA; 6 Spectral Diagnostics, Toronto, ON, Canada; 7 Brigham
and Women’s Hospital, Boston, MA
Mucosal barrier injury caused by HSCT chemoradiotherapy
conditioning leads to translocation of bacteria and bacterial prod-
ucts, including LPS-bearing bacteria and free LPS, into the sys-
temic circulation. LPS signaling through its TLR4 receptor
results in inflammatory cytokine release and resulting hypotension,
fever, coagulopathy and end organ dysfunction. In allogeneic mu-
rine HSCT models, prior immunization to LPS, blockade of
LPS:TLR4 signaling and use of LPS hyporesponsive mice all de-
crease HSCT morbidity and mortality, particularly acute GVHD
and interstitial pneumonia. As humans are both very LPS sensitive
and known to be endotoxemic early peri-HSCT, we initiated
a cohort dose escalation Phase I/II study of rBPI21, a recombinant
fragment of a neutrophil granule cationic protein with potent LPS-
neutralizing activity in vivo, in patients (pts) undergoing conven-
tional allogeneic myeloablative HSCT with sibling or unrelatedPBSC or BM. The first cohort (CHT1) filled with 6 pts aged
17-65 (median 54 yrs). Pts received 4 mg/kg bolus IV rBPI21 Day
(D) -1 followed by 6 mg/kg/D continuous IV for 3 D. No severe
adverse events (AE) were seen. A prospective observational
HSCT study (OBS) enrolled 13 pts aged 35-59 (median 48) meet-
ing trial eligibility who gave blood samples on the same schedule.
All CHT1 AE through discharge were # Grade (Gr) 3. 10 Gr 3
AEs were seen: mucositis (3), infections (ID,5), and hypertension
(2). In OBS, pts had 23 Gr 3, 7 Gr 4 and 3 Gr 5 AE – Gr 3: mu-
cositis (7), ID (10), hyper/hypotension (2), liver (3), renal (1); Gr
4:cardiac (3), mucositis (2), liver (1), ID (1); Gr 5: 1 each VOD,
ARDS, DAH. Time to engraftment was the same. LPS, by endo-
toxin activity assay (EAA, Spectral Diagnostics), and cytokine levels
were drawn before conditioning, D -1 (pre rBPI21), D0, D2 (end of
rBPI21) and weekly to D21. CHT1 EAA levels were\OBS at all
timepoints, p \ .033 at D2. IL6 levels, reflective of bioactive
LPS, increased less from baseline in CHT1 at all timepoints vs
OBS, p\ .014 D 14. Other assays are in process. The trial closed
after CHT1 due to rBPI21 supply issues. However, this first human
trial of LPS neutralization during HSCT supports feasibility and
tolerability. There is encouraging evidence of bioactivity, and pos-
sible decreased HSCT morbidity, at a biologically suboptimal dose.
Additional studies with this or similar LPS antagonists should be
performed to fully evaluate potential efficacy in attenuating
HSCT toxicity including GVHD.270
CLOSTRIDIUM DIFFICILE-ASSOCIATED DISEASE IN HEMATAPOETIC
STEM CELL TRANSPLANTATION RECIPIENTS
Trifilio, S., Pi, J., Mehta, J. Northwestern Memorial Hospital, Chicago,
IL
Clostridium Difficile-associated disease(CDAD) is a source of
morbidity and mortality for hematapoetic stem cell transplantation
recipients(HSCT). Risk factors for the development of CDAD are
largely unknown. We retrospectively reviewed 822 HSCT recipient
charts for the incidence of CDAD and evaluated risk factors and out-
comes associated with CDAD.
Methods: 822 consecutive HSCT recipients(615 autologous/207 al-
logeneic) from Northwestern Memorial Hospital (NMH)between
2004-08 were reviewed. CDAD was evaluated from the day of admis-
sion until dischage following HSCT. All patients received acyclovir,
ciprofloxacin and an azole as prophylaxis. Cefepime(CEF) or Piper-
acillin/Tazobactam(P/T) were initiated for neutropenic(NTP) fe-
ver. Due to NMH policy changes, 50% of patients received a low
microbial diet, while 50% did not. Bivariate analysis was used to eval-
uate the correlation between CDAD and dependent variables. This
study was approved by NMH IRB.
Results: Results for 83 patients identified with CDAD are listed in
table 1.There was a significant difference in the incidence of
CDAD between autologous and allogeneic HSCT 14.5% vs
8.5%: p5 .023)respectively. There was no association between
CDAD and age, sex, diagnosis, or conditioning regimen(except
more CDAD patients received RIST:p5 .027). Median time to oc-
currence of CDAD was 8days post-HSCT. Time to engraftment
was similar for CDAD and non-CDAD HSCT recipients(12 and
11 days respectively). A significant correlation was found between
patients who were colonized with VRE and subsequent develop-
ment of CDAD(p5 .0014). Patients who were fed a low microbial
diet(auto/allo matched) were also at increased risk for CDAD (51/
411 vs 32/411:p5 .05). Neither CEF nor P/T treatment was asso-
ciated with CDAD. Vancomycin use was associated with increased
risk for CDAD although patients were initiated only 1 day(median)
prior to CDAD. No correlation was found between patients who
developed NTP fever during HSCT and CDAD and the number
of co-infections was similar in CDAD and non-CDAD patients.
11/30 allo HSCT recipients who had CDAD developed Grade 3-
4 GI GVH within 30d of CDAD treatment. Overall inpatient mor-
tality was significantly greater for patients with CDAD(7/82 vs 25/
740: p5 .032)
Conclusion: CDAD poses a risk for increased morbidity and mor-
tality for recipients of HSCT. Identification and correction of
